[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20002957L - Behandling med anti-ErbB2-antistoffer - Google Patents

Behandling med anti-ErbB2-antistoffer

Info

Publication number
NO20002957L
NO20002957L NO20002957A NO20002957A NO20002957L NO 20002957 L NO20002957 L NO 20002957L NO 20002957 A NO20002957 A NO 20002957A NO 20002957 A NO20002957 A NO 20002957A NO 20002957 L NO20002957 L NO 20002957L
Authority
NO
Norway
Prior art keywords
treatment
erbb2 antibodies
erbb2
antibodies
Prior art date
Application number
NO20002957A
Other languages
English (en)
Other versions
NO20002957D0 (no
Inventor
Steven Shak
Virginia E Paton
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22088358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20002957(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20002957D0 publication Critical patent/NO20002957D0/no
Publication of NO20002957L publication Critical patent/NO20002957L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20002957A 1997-12-12 2000-06-09 Behandling med anti-ErbB2-antistoffer NO20002957L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6934697P 1997-12-12 1997-12-12
PCT/US1998/026266 WO1999031140A1 (en) 1997-12-12 1998-12-10 TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Publications (2)

Publication Number Publication Date
NO20002957D0 NO20002957D0 (no) 2000-06-09
NO20002957L true NO20002957L (no) 2000-08-11

Family

ID=22088358

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20002957A NO20002957L (no) 1997-12-12 2000-06-09 Behandling med anti-ErbB2-antistoffer
NO20091147A NO20091147L (no) 1997-12-12 2009-03-17 Behandling med anti-ErbB2-antistoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20091147A NO20091147L (no) 1997-12-12 2009-03-17 Behandling med anti-ErbB2-antistoff

Country Status (18)

Country Link
US (11) US7846441B1 (no)
EP (3) EP2275450A1 (no)
JP (7) JP2002508397A (no)
KR (7) KR20100135337A (no)
CN (2) CN1269839C (no)
AR (1) AR020051A1 (no)
AU (1) AU1908199A (no)
BR (1) BR9815363A (no)
CA (2) CA2730373A1 (no)
DK (1) DK1037926T3 (no)
ES (1) ES2450922T3 (no)
HK (2) HK1030784A1 (no)
IL (4) IL136201A0 (no)
NO (2) NO20002957L (no)
NZ (1) NZ504597A (no)
TR (1) TR200001689T2 (no)
WO (1) WO1999031140A1 (no)
ZA (1) ZA9811162B (no)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6972170B1 (en) 1997-12-01 2005-12-06 Sloan-Kettering Institute For Cancer Research Markers for prostate cancer
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6333348B1 (en) 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
DK1187632T3 (da) * 1999-05-14 2009-04-06 Genentech Inc Behandling med anti-ErbB2-antistoffer
CA2370466C (en) * 1999-06-25 2011-02-08 Sharon Erickson Methods of treatment using anti-erbb antibody-maytansinoid conjugates
EP1512755A3 (en) * 1999-06-10 2007-11-21 Sloan-Kettering Institute For Cancer Research Markers for prostate cancer
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
PT1189634E (pt) * 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CH694589A5 (de) * 1999-06-25 2005-04-15 Genentech Inc Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern.
EP1189931B1 (en) 1999-07-02 2006-06-21 Genentech, Inc. Peptide compounds that bind her2
GB9917012D0 (en) * 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
JP2003505432A (ja) 1999-07-23 2003-02-12 グラクソ グループ リミテッド 抗ｅｐ−ｃａｍ抗体と化学療法剤との組合せ
EP1246597B1 (en) * 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
IL148114A0 (en) * 1999-08-27 2002-09-12 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU3458401A (en) 2000-01-25 2001-08-07 Genentech Inc. Compositions and methods for treatment of cancer
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
JP2003527441A (ja) * 2000-03-22 2003-09-16 グラクソ グループ リミテッド 細胞周期を阻止する薬剤及び抗体を含む医薬
MXPA02011194A (es) * 2000-05-15 2003-03-10 Pharmacia Italia Spa Inhibidores de aromatasa y anticuerpos anti-her2 monoclonales como agentes antitumorales.
PL217410B1 (pl) * 2000-05-19 2014-07-31 Genentech Inc Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
WO2002087618A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
WO2002087619A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
EP1495055B1 (en) * 2002-04-18 2013-08-14 Genencor International, Inc. Production of functional antibodies in filamentous fungi
EP1532993A4 (en) 2002-05-30 2010-09-29 Toray Industries ADSORBENT OF IMMUNOSUPPRESSIVE SUBSTANCE, EXTRACORPOREAL CIRCULATION COLUMN, AND METHOD OF TREATING CANCER
AU2002951853A0 (en) * 2002-10-04 2002-10-24 Commonwealth Scientific And Industrial Research Organisation Crystal structure of erbb2 and uses thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
PT1771482E (pt) 2004-07-22 2014-11-03 Genentech Inc Composição de anticorpo her2
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2007125644A (ru) * 2004-12-07 2009-01-20 Дженентек Инк. (Us) Отбор пациентов для терапии ингибитором her
WO2006078307A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
WO2006086730A2 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
BRPI0606542A8 (pt) * 2005-02-23 2018-03-20 Genentech Inc métodos para aumentar o tempo de progressão de uma doença (ttp)
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
CA2612394C (en) 2005-06-15 2017-02-21 The Ohio State University Research Foundation Her-2 peptides
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
JP2009511892A (ja) * 2005-10-11 2009-03-19 ドマンティス リミテッド 抗体ポリペプチドライブラリーのスクリーニングと選択された抗体ポリペプチド
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MY150756A (en) 2006-08-21 2014-02-28 Hoffmann La Roche Tumor theraphy with an anti-vegf antibody
ES2477497T3 (es) 2007-03-02 2014-07-17 Genentech, Inc. Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
US8557588B2 (en) * 2007-03-27 2013-10-15 Schlumberger Technology Corporation Methods and apparatus for sampling and diluting concentrated emulsions
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
WO2008150485A2 (en) * 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2219602A1 (en) * 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
BRPI0812682A2 (pt) * 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CA2779436A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
ES2535404T5 (es) 2008-11-22 2018-11-19 F. Hoffmann-La Roche Ag Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
PL2536748T3 (pl) 2010-02-18 2015-01-30 Genentech Inc Antagoniści neureguliny i ich zastosowanie w leczeniu nowotworu
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
CN103080136B (zh) 2010-06-18 2015-08-12 霍夫曼-拉罗奇有限公司 抗Axl抗体及使用方法
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN101974535B (zh) * 2010-11-03 2012-12-19 北京天广实生物技术股份有限公司 新型抗ErbB2人源化抗体MIL12的制备及其应用
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
JP2014526891A (ja) 2011-08-17 2014-10-09 ジェネンテック， インコーポレイテッド ニューレグリン抗体とその使用
JP6297490B2 (ja) * 2011-08-31 2018-03-20 ジェネンテック， インコーポレイテッド 診断マーカー
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
WO2014060365A1 (en) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
CA2908391A1 (en) 2013-05-01 2014-11-06 Five Prime Therapeutics, Inc. Methods of treating cancer
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
SI3302551T1 (sl) 2015-05-30 2024-10-30 F. Hoffmann-La Roche Ag Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN115317603A (zh) 2016-07-07 2022-11-11 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
CA3040913A1 (en) 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
KR102313262B1 (ko) 2016-12-28 2021-10-14 제넨테크, 인크. 진행성 her2 발현 암의 치료
WO2018136412A2 (en) 2017-01-17 2018-07-26 Genentech, Inc. Subcutaneous her2 antibody formulations
WO2018160654A2 (en) 2017-03-02 2018-09-07 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
JP2020517273A (ja) 2017-04-24 2020-06-18 ジェネンテック， インコーポレイテッド 膜貫通ドメインまたは膜近傍ドメインにおけるＥｒｂＢ２／Ｈｅｒ２突然変異
JP2019043214A (ja) 2017-08-30 2019-03-22 いすゞ自動車株式会社 ステアリング装置
CN112823168A (zh) 2018-10-08 2021-05-18 苏黎世大学 结合her2的四聚体多肽
CN113993549A (zh) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 靶向her2的免疫缀合物
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444960A (en) * 1891-01-20 Fence or gate
US4017471A (en) 1975-09-15 1977-04-12 G. D. Searle & Co. Immunological compounds
US4935341A (en) 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4994558A (en) 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68924979T2 (de) 1988-04-18 1996-10-24 Oncogene Science Inc Nachweis der expression von neu genen und produkten.
JP2761543B2 (ja) 1988-08-17 1998-06-04 味の素株式会社 ヒト癌原遺伝子産物に対するモノクローナル抗体及びそれを産生するハイブリドーマ
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
AU645760B2 (en) 1989-08-04 1994-01-27 Berlex Laboratories, Inc. C-erbb-2 external domain: GP75
JP2895105B2 (ja) 1989-09-14 1999-05-24 株式会社ニチレイ ｃ‐ｅｒｂＢ‐２癌遺伝子産物をイムノアッセイする乳癌の血清診断法とそのキット
DE68926248T2 (de) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE153858T1 (de) 1990-04-06 1997-06-15 Univ Pennsylvania Ligand für das neu-gen-produkt
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
DE69228300T2 (de) 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
US5288477A (en) 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
WO1994000136A1 (en) 1992-06-30 1994-01-06 Oncologix, Inc. A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU3236793A (en) 1991-12-12 1993-07-19 Berlex Laboratories, Inc. Recombinant and chimeric antibodies to c-erbB-2
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
IT1257898B (it) * 1992-06-16 1996-02-16 Procedimento ed apparecchiatura per la produzione, in particolare domestica, di bevande.
AU5355594A (en) 1992-10-09 1994-05-09 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
DK0616812T3 (da) 1993-03-24 2000-04-25 Berlex Biosciences Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer
WO1994022478A1 (en) 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
US5430620A (en) 1993-10-08 1995-07-04 Cogent Light Technologies, Inc. Compact surgical illumination system capable of dynamically adjusting the resulting field of illumination
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO1995030331A1 (en) 1994-05-05 1995-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
DE69504278T2 (de) 1994-11-10 1999-05-06 Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum, 72076 Tuebingen Verfahren zur Wachstumshemmung von Leukämischen Zellen durch HER-2-Protein-Zeilen
WO1996016673A1 (en) 1994-12-02 1996-06-06 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
EP0828767B1 (en) * 1995-05-26 2003-07-30 Igen, Inc. Molecularly imprinted beaded polymers and stabilized suspension polymerization of the same in perfluorocarbon liquids
JP3354035B2 (ja) * 1995-05-31 2002-12-09 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
EP0873363B1 (en) 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
EP0894139A1 (en) 1996-03-20 1999-02-03 Board Of Regents The University Of Texas System Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US5925519A (en) 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
JP2001504326A (ja) 1996-10-18 2001-04-03 ジェネンテック インコーポレーテッド 抗ＥｒｂＢ２抗体
AU5243198A (en) 1996-10-30 1998-05-22 Uab Research Foundation, The Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
US20030171551A1 (en) 1997-01-31 2003-09-11 Joseph D. Rosenblatt Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999048527A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
ES2198913T5 (es) 1998-05-06 2013-11-18 Genentech, Inc. Purificación de proteínas mediante cromatografía de intercambio iónico
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6333348B1 (en) 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
DK1187632T3 (da) 1999-05-14 2009-04-06 Genentech Inc Behandling med anti-ErbB2-antistoffer
PT1189634E (pt) 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
IL148114A0 (en) 1999-08-27 2002-09-12 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
MXPA02011194A (es) 2000-05-15 2003-03-10 Pharmacia Italia Spa Inhibidores de aromatasa y anticuerpos anti-her2 monoclonales como agentes antitumorales.
PL217410B1 (pl) 2000-05-19 2014-07-31 Genentech Inc Zastosowanie antagonisty ErbB, antagonista ErbB do zastosowania w metodzie leczenia raka i sposób identyfikacji pacjenta skłonnego do korzystnej odpowiedzi na antagonistę ErbB przy leczeniu raka
AU2002239486A1 (en) 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
KR20030068205A (ko) 2001-01-09 2003-08-19 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
JP2006516117A (ja) 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
WO2005099756A2 (en) 2004-04-08 2005-10-27 Agus David B ErbB ANTAGONISTS FOR PAIN THERAPY
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
PT1771482E (pt) 2004-07-22 2014-11-03 Genentech Inc Composição de anticorpo her2
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2007125644A (ru) 2004-12-07 2009-01-20 Дженентек Инк. (Us) Отбор пациентов для терапии ингибитором her
WO2006078307A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
BRPI0606542A8 (pt) * 2005-02-23 2018-03-20 Genentech Inc métodos para aumentar o tempo de progressão de uma doença (ttp)
TW200642695A (en) 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
JP2009539836A (ja) 2006-06-05 2009-11-19 ジェネンテック・インコーポレーテッド ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長
JP5317084B2 (ja) 2006-11-08 2013-10-16 国立大学法人愛媛大学 π共役環状化合物およびその製造方法
ES2477497T3 (es) * 2007-03-02 2014-07-17 Genentech, Inc. Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
JP5117165B2 (ja) 2007-11-09 2013-01-09 花王株式会社 水中油型乳化組成物の製造方法
JP5170667B2 (ja) 2008-06-02 2013-03-27 小林クリエイト株式会社 情報隠蔽帳票
BRPI0812682A2 (pt) * 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP5213775B2 (ja) 2009-03-25 2013-06-19 株式会社ジャパンディスプレイウェスト 電気光学装置および電子機器

Also Published As

Publication number Publication date
US8075892B2 (en) 2011-12-13
KR20120062942A (ko) 2012-06-14
KR20150013870A (ko) 2015-02-05
US20190240185A1 (en) 2019-08-08
ZA9811162B (en) 2000-06-07
CN1281468A (zh) 2001-01-24
US8642036B2 (en) 2014-02-04
CN1820734A (zh) 2006-08-23
US7846441B1 (en) 2010-12-07
US20040037823A9 (en) 2004-02-26
ES2450922T3 (es) 2014-03-25
KR20130036367A (ko) 2013-04-11
AR020051A1 (es) 2002-04-10
US8309087B2 (en) 2012-11-13
US20130209459A1 (en) 2013-08-15
US20120034213A1 (en) 2012-02-09
JP2017039737A (ja) 2017-02-23
US20080187533A1 (en) 2008-08-07
US7892549B2 (en) 2011-02-22
CA2311409C (en) 2011-04-12
BR9815363A (pt) 2001-10-16
DK1037926T3 (en) 2014-03-03
EP2275450A1 (en) 2011-01-19
JP2019055979A (ja) 2019-04-11
HK1030784A1 (en) 2001-05-18
JP2017165737A (ja) 2017-09-21
IL234696A (en) 2017-06-29
KR20100135337A (ko) 2010-12-24
JP2016006046A (ja) 2016-01-14
US8425908B2 (en) 2013-04-23
IL214084A (en) 2015-02-26
KR20010033019A (ko) 2001-04-25
IL136201A0 (en) 2001-05-20
JP2013056887A (ja) 2013-03-28
NO20091147L (no) 2000-08-11
IL136201A (en) 2011-08-31
JP2010209081A (ja) 2010-09-24
WO1999031140A1 (en) 1999-06-24
CN1820734B (zh) 2011-06-15
JP2002508397A (ja) 2002-03-19
NO20002957D0 (no) 2000-06-09
US20110250194A1 (en) 2011-10-13
TR200001689T2 (tr) 2001-01-22
HK1091391A1 (en) 2007-01-19
NZ504597A (en) 2003-05-30
US20140341886A1 (en) 2014-11-20
US20030170234A1 (en) 2003-09-11
KR20180107323A (ko) 2018-10-01
US20050002928A1 (en) 2005-01-06
CA2730373A1 (en) 1999-06-24
IL214084A0 (en) 2011-08-31
KR20080075042A (ko) 2008-08-13
US20030147884A1 (en) 2003-08-07
EP2277919A1 (en) 2011-01-26
CA2311409A1 (en) 1999-06-24
US20070292419A1 (en) 2007-12-20
CN1269839C (zh) 2006-08-16
EP1037926A1 (en) 2000-09-27
AU1908199A (en) 1999-07-05
EP1037926B1 (en) 2014-01-15

Similar Documents

Publication Publication Date Title
NO20002957L (no) Behandling med anti-ErbB2-antistoffer
DK1189641T3 (da) Humaniserede ANTI-ErbB2-antistoffer og behandling med ANTI-ErbB2-antistoffer
DE69729672D1 (de) Biosensor
DE69935516D1 (de) Antikörper mit verbesserter produzierbarkeit
CY2005008I2 (el) Αντισωματα αντι - vegf
FI952093A0 (fi) Kapsling foer med akustiska ytvaogefunktionerande byggelement
FI974269A0 (fi) Radiosaendare-mottagarestruktur med tvao frekvensomraoden
FI972664A0 (fi) Foerseglad saeck med avluftning
FR2765954B3 (fr) Radiant
DK1019042T3 (da) Forbindelser med anti-første-passagevirkning
FI970405A0 (fi) Plattformad traeprodukt med skiktstruktur
FI974544A0 (fi) Anordning i en med manoeverplats foersedd lastkran
FI970017A0 (fi) Med lampeffekts maetning foersett reglerbart elektroniskt anslutningsorgan
FI974641A0 (fi) SOP-/torkanordning med loestagbart skaft
FI972507A0 (fi) Graesklippningssax med skaft
FI970473A0 (fi) Vaextextraktblandning med antiherpasaktivitet
FI973903A0 (fi) Rundbalshack med cylindrisk behaollarew
FI973862A0 (fi) Isborr med fasningsskaer
FI973598A0 (fi) Lastutrymme med utskjutbart golv
FI972274A0 (fi) Foerfarande foer roekgasrening med snabba elektroner
FI971819A0 (fi) Borste med stoed
FI970870A0 (fi) Tvaettlapp med oerter
FI974642A0 (fi) Arbetsbord med tvaettho
FI971071A0 (fi) Minneselement i samband med medicinfoerpackning
FI1857U1 (fi) Kantele med mekanik